Arkolith/Insider Trading/KIN/Form 4

Veszpremi Ervin

DirectorKindred Biosciences, Inc. (KIN) · full profile →Form 4 · filed Aug 30, 2021
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
10
0 non-derivative · 10 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 27, 2021Disposed to issuer(D)40K$8.93$357K0
Aug 27, 2021Disposed to issuer(D)20K$7.88$158K0
Aug 27, 2021Disposed to issuer(D)35K—$00
Aug 27, 2021Disposed to issuer(D)44K$2.29$101K0
Aug 27, 2021Disposed to issuer(D)50K$4.81$241K0
Aug 27, 2021Disposed to issuer(D)50K$2.85$142K0
Aug 27, 2021Disposed to issuer(D)75K$0.50$38K0
Aug 27, 2021Disposed to issuer(D)50K—$00
Aug 27, 2021Disposed to issuer(D)50K—$00
Aug 27, 2021Disposed to issuer(D)44K$5.80$255K0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001250853-21-000088) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML